Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages

被引:58
|
作者
Chinetti-Gbaguidi, G
Rigamonti, E
Helin, L
Mutka, AL
Lepore, M
Fruchart, JC
Clavey, V
Ikonen, E
Lestavel, S
Staels, B [1 ]
机构
[1] Inst Pasteur, INSERM, UR 545, F-59019 Lille, France
[2] Univ Lille 2, Lille, France
[3] Univ Helsinki, Inst Biotechnol, Helsinki, Finland
关键词
nuclear receptors; gene regulation; atherosclerosis; cholesterol homeostasis;
D O I
10.1194/jlr.M500326-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mobilization of cholesterol from intracellular pools to the plasma membrane is a determinant that governs its availability for efflux to extracellular acceptors. NPC1 and NPC2 are proteins localized in the late endosome and control cholesterol transport from the lysosome to the plasma membrane. Here, we report that NPC1 and NPC2 gene expression is induced by oxidized LDL ( OxLDL) in human macrophages. Because OxLDLs contain natural activators of peroxisome proliferator-activated receptor alpha (PPAR alpha),a fatty acid-activated nuclear receptor, the regulation of NPC1 and NPC2 by PPAR alpha and the consequences on cholesterol trafficking were further studied. NPC1 and NPC2 expression is induced by synthetic PPAR alpha ligands in human macrophages. Furthermore, PPAR alpha activation leads to an enrichment of cholesterol in the plasma membrane. By contrast, incubation with progesterone, which blocks postlysosomal cholesterol trafficking, as well as NPC1 and NPC2 mRNA depletion using small interfering RNA, abolished ABCA1-dependent cholesterol efflux induced by PPAR alpha activators. These observations identify a novel regulatory role for PPAR alpha in the control of cholesterol availability for efflux that, associated with its ability to inhibit cholesterol esterification and to stimulate ABCA1 and scavenger receptor class B type I expression, may contribute to the stimulation of reverse cholesterol transport.
引用
收藏
页码:2717 / 2725
页数:9
相关论文
共 50 条
  • [31] Peroxisome proliferator-activated receptor γ (PPARγ) and sepsis
    von Knethen, Andreas
    Soller, Mathias
    Bruene, Bernhard
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2007, 55 (01) : 19 - 25
  • [33] Peroxisome proliferator-activated receptor γ (PPARγ) and sepsis
    Andreas von Knethen
    Mathias Soller
    Bernhard Brüne
    Archivum Immunologiae et Therapiae Experimentalis, 2007, 55 : 19 - 25
  • [34] Evolution of peroxisome proliferator-activated receptor agonists
    Chang, Feng
    Jaber, Linda A.
    Berlie, Helen D.
    O'Connell, Mary Beth
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (06) : 973 - 983
  • [35] Peroxisome proliferator-activated receptor γ in diabetes and metabolism
    Rangwala, SM
    Lazar, MA
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (06) : 331 - 336
  • [36] PHYSIOLOGICAL FUNCTIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR β
    Neels, Jaap G.
    Grimaldi, Paul A.
    PHYSIOLOGICAL REVIEWS, 2014, 94 (03) : 795 - 858
  • [37] Peroxisome proliferator-activated receptor-γ and lipodystrophy
    Tantsma, Jouke T.
    Rabelink, Ton J.
    FUTURE LIPIDOLOGY, 2006, 1 (04): : 455 - 462
  • [38] ENANTIOSELECTIVE ACTIVATION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
    BOIE, Y
    ADAM, M
    RUSHMORE, TH
    KENNEDY, BP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (08) : 5530 - 5534
  • [39] Peroxisome proliferator-activated receptor γ in malignant diseases
    Wang, TT
    Xu, J
    Yu, XF
    Yang, RC
    Han, ZC
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (01) : 1 - 14
  • [40] Leptin and peroxisome proliferator-activated receptor gamma
    Kim, Y. S.
    Kim, H. H.
    Kang, Y. K.
    Moon, J. S.
    Kwon, S. O.
    Oh, M. K.
    Cha, I. H.
    Kim, S. Y.
    Kim, J. N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 110 - 110